Such studies, which can be addressed through xenograft models, would likely also require the introduction of one or more of the common SETD2 co‐occurring mutations in ccRCC such as VHL and/or PBRM1, as noted above. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.